Polyunsaturated fatty acids (PUFAs), particularly omega-3 fatty acids found in fish oil (e.g., eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), have been investigated for their role in managing psoriasis, a chronic inflammatory skin disorder. The rationale for their use stems from the anti-inflammatory properties of omega-3 PUFAs, which are thought to reduce the production of pro-inflammatory cytokines and eicosanoids involved in psoriatic pathophysiology.

Several small clinical trials and observational studies have explored the effects of fish oil supplementation in psoriasis patients. Some studies report modest improvements in psoriasis severity, erythema, and scaling, particularly when high doses are used or when combined with conventional therapy. However, results are inconsistent, with other studies failing to demonstrate significant benefit over placebo. A 2014 systematic review (Am J Clin Dermatol) concluded that while there is some evidence for beneficial effects, the quality of the data is generally low and results are mixed. Major guidelines recognize the potential but do not recommend PUFAs as a first-line or stand-alone treatment.

In summary, there is scientific investigation—though not robust or conclusive—supporting the adjunctive use of polyunsaturated fatty acids, especially omega-3s, in psoriasis. The overall evidence is limited (rated 2/5), and more rigorous, large-scale randomized controlled trials are needed to confirm efficacy and establish guidelines for their use in this condition.